JP2020526575A5 - - Google Patents

Download PDF

Info

Publication number
JP2020526575A5
JP2020526575A5 JP2020519196A JP2020519196A JP2020526575A5 JP 2020526575 A5 JP2020526575 A5 JP 2020526575A5 JP 2020519196 A JP2020519196 A JP 2020519196A JP 2020519196 A JP2020519196 A JP 2020519196A JP 2020526575 A5 JP2020526575 A5 JP 2020526575A5
Authority
JP
Japan
Prior art keywords
migraine
leucine
pharmaceutical composition
acceptable salt
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020519196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526575A (ja
JP7130739B2 (ja
Filing date
Publication date
Priority claimed from GBGB1709459.0A external-priority patent/GB201709459D0/en
Application filed filed Critical
Publication of JP2020526575A publication Critical patent/JP2020526575A/ja
Publication of JP2020526575A5 publication Critical patent/JP2020526575A5/ja
Application granted granted Critical
Publication of JP7130739B2 publication Critical patent/JP7130739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020519196A 2017-06-14 2018-06-25 片頭痛の治療 Active JP7130739B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine

Publications (3)

Publication Number Publication Date
JP2020526575A JP2020526575A (ja) 2020-08-31
JP2020526575A5 true JP2020526575A5 (cg-RX-API-DMAC10.html) 2021-08-12
JP7130739B2 JP7130739B2 (ja) 2022-09-05

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519196A Active JP7130739B2 (ja) 2017-06-14 2018-06-25 片頭痛の治療

Country Status (25)

Country Link
US (1) US11471434B2 (cg-RX-API-DMAC10.html)
EP (1) EP3638370B1 (cg-RX-API-DMAC10.html)
JP (1) JP7130739B2 (cg-RX-API-DMAC10.html)
KR (1) KR102594130B1 (cg-RX-API-DMAC10.html)
CN (1) CN111093772B (cg-RX-API-DMAC10.html)
AU (1) AU2018284330B2 (cg-RX-API-DMAC10.html)
CY (1) CY1123860T1 (cg-RX-API-DMAC10.html)
DK (1) DK3638370T3 (cg-RX-API-DMAC10.html)
ES (1) ES2847169T3 (cg-RX-API-DMAC10.html)
GB (1) GB201709459D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20210108T1 (cg-RX-API-DMAC10.html)
HU (1) HUE053089T2 (cg-RX-API-DMAC10.html)
IL (1) IL271211B2 (cg-RX-API-DMAC10.html)
LT (1) LT3638370T (cg-RX-API-DMAC10.html)
MA (1) MA49396B1 (cg-RX-API-DMAC10.html)
MD (1) MD3638370T2 (cg-RX-API-DMAC10.html)
MX (1) MX387909B (cg-RX-API-DMAC10.html)
PL (1) PL3638370T3 (cg-RX-API-DMAC10.html)
PT (1) PT3638370T (cg-RX-API-DMAC10.html)
RS (1) RS61481B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201912146RA (cg-RX-API-DMAC10.html)
SI (1) SI3638370T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202100037T1 (cg-RX-API-DMAC10.html)
WO (1) WO2018229738A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201908087B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65663B1 (sr) 2018-02-15 2024-07-31 Intrabio Ltd Acetil leucin za upotrebu u lečenju sindroma nemirnih nogu
CN120157593A (zh) * 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
ES2322707T3 (es) * 2003-07-03 2009-06-25 Euro-Celtique S.A. Derivados de 2-piridina alquino utiles para tratar el dolor.
ES2327684T3 (es) * 2003-07-24 2009-11-02 Euro-Celtique S.A. Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor.
SI1664041T1 (sl) * 2003-09-22 2008-12-31 Euro Celtique Sa Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
MXPA06003123A (es) * 2003-09-22 2006-05-31 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor.
ES2322907T3 (es) * 2003-12-30 2009-07-01 Euro-Celtique S.A. Piperazinas utiles para el tratamiento de dolor.
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
US8921373B2 (en) * 2010-06-22 2014-12-30 Shionogi & Co., Ltd. Compounds having TRPV1 antagonistic activity and uses thereof
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
MX376862B (es) 2010-11-09 2025-03-07 Mannkind Corp Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
US9394293B2 (en) * 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
PT3445351T (pt) 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
TN2019000033A1 (fr) 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
PT3482754T (pt) 2016-08-11 2021-02-03 Intrabio Ltd Composições farmacêuticas e utilizações contra os distúrbios de armazenamento lisossómico
PT3600276T (pt) 2017-03-28 2023-07-11 Intrabio Ltd Beta-histina, ou um seu sal farmaceuticamente aceitável, e um inibidor da monoamina oxidase, para utilização no tratamento ou prevenção de um ou mais sintomas de vertigem num indivíduo
US11793782B2 (en) 2017-10-18 2023-10-24 Intrabio Limited Therapeutic agents for neurodegenerative diseases
EP3697406A1 (en) 2017-10-18 2020-08-26 IntraBio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
RS65663B1 (sr) 2018-02-15 2024-07-31 Intrabio Ltd Acetil leucin za upotrebu u lečenju sindroma nemirnih nogu
CN120157593A (zh) 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
CN119097618A (zh) 2019-03-02 2024-12-10 内在生物技术有限公司 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Similar Documents

Publication Publication Date Title
JP2022153638A5 (cg-RX-API-DMAC10.html)
JP2026035701A5 (cg-RX-API-DMAC10.html)
JP2023181322A (ja) 睡眠時無呼吸を治療するための方法および組成物
IL315023A (en) Neuroactive steroids for treatment of cns-related disorders
JP2020516646A5 (cg-RX-API-DMAC10.html)
JPWO2019065900A1 (ja) 神経変性疾患あるいは認知機能障害の予防または治療剤としてのr−ケタミンおよびその誘導体
JP2023500032A5 (cg-RX-API-DMAC10.html)
JP2023552700A5 (cg-RX-API-DMAC10.html)
JP2023073373A5 (cg-RX-API-DMAC10.html)
JP2007182440A (ja) アゴメラチンの、口腔粘膜または舌下投与のための口内分散性医薬組成物
JP2021530543A5 (cg-RX-API-DMAC10.html)
JP2025508004A5 (cg-RX-API-DMAC10.html)
JP2016505050A5 (cg-RX-API-DMAC10.html)
AU1774192A (en) Composition and method containing optically pure (s) metoprolol
CN101610760A (zh) 恶病质的治疗
JP2020526575A (ja) 片頭痛の治療
JP2025508051A5 (cg-RX-API-DMAC10.html)
Moore et al. Management of Motor
JP2024527175A5 (cg-RX-API-DMAC10.html)
JP2023537369A5 (cg-RX-API-DMAC10.html)
Sweet et al. Methyldopa as an adjunct to levodopa treatment of Parkinson's disease
JPWO2022045336A5 (cg-RX-API-DMAC10.html)
JP2021530568A5 (cg-RX-API-DMAC10.html)
JP2022504435A5 (cg-RX-API-DMAC10.html)
JP2015515971A5 (cg-RX-API-DMAC10.html)